Abstract

Aim: To prevent thrombotic complications in carotid artery stenting (CAS), it is recommended to use acetylsalicylic acid (ASA) and clopidogrel for at least one month, followed by single antiplatelet therapy. The number of studies on the use of ticagrelor in CAS is very few. We aimed to evaluate the efficacy and safety of ticagrelor in CAS in this study.

Methods: The records of the patients who underwent CAS between January 2020 and January 2022 were scanned and the patients who were treated with the ASA and ticagrelor therapy were included in this study. Demographic data of the patients, vascular risk factors, ipsilateral-contralateral stenosis rates, balloon angioplasty application status, residual stenosis rates, periprocedural ischemic and hemorrhagic events, and vascular events developed during three-month follow-up were noted.

Results: Thirteen patients were included in the present study. Their mean age was 69.38±7.1 years. The mean carotid stenosis rate was 82.07±10.44%, and contralateral stenosis rate was 65.07±32.98%. Stent thrombosis was not observed in any patient. After the procedure, minor ischemic stroke that did not cause disability developed in one patient and puncture site bleeding that did not require transfusion in one patient. One patient had >50% restenosis at three months.

Conclusion: The findings suggest that dual antiplatelet therapy with ticagrelor + ASA appears to be a safe and effective treatment for CAS. Given that clopidogrel resistance cannot be evaluated in many centers, it may be more accurate to prefer ticagrelor, especially in high-risk patients with bilateral stenosis.

Keywords: Carotid artery, clopidogrel, stent, stroke, ticagrelor

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Yabalak A. The efficacy and safety of carotid stenting under dual antiplatelet therapy with ticagrelor and acetylsalicylic acid. Northwestern Med J. 2023;3(3):165-71. https://doi.org/10.54307/NWMJ.2023.63497

References

  1. Halliday A, Bulbulia R, Bonati LH, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet. 2021; 398(10305): 1065-73. https://doi.org/10.1016/S0140-6736(21)01910-3
  2. Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg. 2011; 54(3): 832-6. https://doi.org/10.1016/j.jvs.2011.07.004
  3. Pandya DJ, Fitzsimmons BFM, Wolfe TJ, et al. Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging. 2010; 20(1): 64-9. https://doi.org/10.1111/j.1552-6569.2008.00322.x
  4. Huibers A, Halliday A, Bulbulia R, Coppi G, de Borst GJ; ACST-2 Collaborative Group. Antiplatelet therapy in carotid artery stenting and carotid endarterectomy in the Asymptomatic Carotid Surgery Trial-2. Eur J Vasc Endovasc Surg. 2016; 51(3): 336-42. https://doi.org/10.1016/j.ejvs.2015.11.002
  5. Hanel RA, Taussky P, Dixon T, et al. Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. J Neurointerv Surg. 2014; 6(4): 320-2. https://doi.org/10.1136/neurintsurg-2013-010699
  6. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014; 34(10): 1077-90. https://doi.org/10.1002/phar.1477
  7. Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010; 121(1): 171-9. https://doi.org/10.1161/CIRCULATIONAHA.109.853069
  8. Ghamraoui AK, Ricotta JJ. Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization. J Vasc Surg. 2021; 73(1): 132-41. https://doi.org/10.1016/j.jvs.2020.04.518
  9. Winter MP, Schneeweiss T, Cremer R, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. 2019; 49(6): e13102. https://doi.org/10.1111/eci.13102
  10. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7): e364-467. https://doi.org/10.1161/STR.0000000000000375
  11. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045-57. https://doi.org/10.1056/NEJMoa0904327
  12. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124(5): 544-54. https://doi.org/10.1161/CIRCULATIONAHA.111.047498
  13. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016; 375(1): 35-43. https://doi.org/10.1056/NEJMoa1603060
  14. Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ. 2019; 365: l2211. https://doi.org/10.1136/bmj.l2211
  15. Wang Y, Lin Y, Meng X, et al. Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. Int J Stroke. 2017; 12(3): 321-5. https://doi.org/10.1177/1747493017694390
  16. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020; 383(3): 207-17. https://doi.org/10.1056/NEJMoa1916870
  17. Amarenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke. 2020; 51(12): 3504-13. https://doi.org/10.1161/STROKEAHA.120.032239
  18. Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. N Engl J Med. 2021; 385(27): 2520-30. https://www.nejm.org/doi/full/10.1056/NEJMoa2111749
  19. Malhotra K, Goyal N, Kasunich AS, et al. Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis. J Neurol Sci. 2018; 390: 212-8. https://doi.org/10.1016/j.jns.2018.05.001
  20. Qureshi AI, Jahngir MU, Qualls K, et al. The effect of ticagrelor on platelet reactivity in patients with clopidogrel resistance undergoing neuroendovascular procedures. J Neuroimaging. 2020; 30(3): 327-34. https://doi.org/10.1111/jon.12714
  21. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol. 2013; 34(4): 716-20. https://doi.org/10.3174/ajnr.A3405
  22. Narata AP, Amelot A, Bibi R, et al. Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: a retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery. 2019; 84(1): 77-83. https://doi.org/10.1093/neuros/nyy002
  23. Karan V, Vyas D, Bohra V, Huded V. Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience. Neurointervention. 2019; 14(2): 125-30. https://doi.org/10.5469/neuroint.2019.00087
  24. Linfante I, Ravipati K, Starosciak AK, Reyes D, Dabus G. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. J Neurointerv Surg. 2021; 13(1): 30-2. https://doi.org/10.1136/neurintsurg-2020-015841
  25. Kadoglou NP, Stasinopoulou M, Giannakopoulos T, et al. The Comparative Effects of Ticagrelor and Clopidogrel on Arterial Injury and In-Stent Restenosis and Thrombosis of Carotid Artery in Atherosclerotic Rabbits. Eur J Vasc Endovasc Surg. 2019; 58(6): e33-4. https://doi.org/10.1016/j.ejvs.2019.06.543
  26. Lotan D, Itsekzon-Hayosh Z, Itelman E, et al. Safety and efficacy of ticagrelor in carotid artery angioplasty in patients with clopidogrel resistance: real life experience. J Am Coll Cardiol. 2020; 75(11 Suppl. 1): 1302. https://doi.org/10.1016/S0735-1097(20)31929-X
  27. Marcaccio C, Patel P, Rastogi V, et al. The Safety and Efficacy of Preoperative Dual Antiplatelet Therapy With Ticagrelor versus Clopidogrel in Patients Undergoing Carotid Artery Stenting. J Vasc Surg. 2021; 74(3): e238-9. https://doi.org/10.1016/j.jvs.2021.06.355
  28. Olafson EM, DeGrote JR, Drofa A, et al. A case series of 18 patients receiving ticagrelor after carotid stenting. J Pharm Pract. 2018; 31(5): 519-21. https://doi.org/10.1177/0897190017729524
  29. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010; 121(10): 1188-99. https://doi.org/10.1161/CIRCULATIONAHA.109.919456